R & D Breakthrough

Many drugs will go off patent by 2005. As a proactive measure to ensure competitive edge in the emerging markets, Orchid has developed non-infringing processes for manufacture of select cephalosporins. This will further strengthen Orchid's position both nationally and internationally, as the new processes developed are being patented worldwide. Further progress has been achieved in antibiotic adduct research, with additional molecules under experimentation with combinations. Orchid's antibiotic adduct research aims to develop antibiotic polymer complexes which utilize a low proportion of standard antibiotic, while achieving equivalent therapeutic efficacy and lower toxicity. Orchid has developed a business plan which includes specific investment for new research and development programs including setting up of the Second R & D Center for New Drug Discovery and Novel Drug Delivery Systems.